Oral medicine center 4 Fokaias STR, 14232, N.Ionia Athens, Greece
Med Oral Patol Oral Cir Bucal. 2021 May 1;26(3):e357-e360. doi: 10.4317/medoral.24230.
Exfoliative and erosive cheilitis, may be a source of speech and chewing discomfort, but may also be an aesthetic issue for the patients affected. Such a clinical presentation may implicate a variety of inflammatory conditions, including atopic (eczematous) cheilitis. Topical and systemic agents, e.g. corticosteroids, have been used to treat inflammatory lip conditions. Topical tacrolimus has also been used in some inflammatory lip conditions.
We performed a retrospective clinical analysis of atopic cheilitis patients.
Between 2015 and 2020, we addressed 7 (seven) patients with atopic dermatitis affecting only lips and were diagnosed as atopic-eczematous cheilitis. They were treated with 0.03 per cent topical tacrolimus ointment and responded completely.
These cases represent an underreported atopy / eczema event;-few cases of atopic cheilitis without concomitant dermal lesions appear in the literature. We are also showing and discussing yet another application of tacrolimus in a local atopic form of inflammation affecting the lips.
剥脱性和糜烂性唇炎，可能是言语和咀嚼不适的原因，也可能是受影响患者的美学问题。这种临床表现可能涉及多种炎症性疾病，包括特应性（湿疹样）唇炎。局部和全身药物，如皮质类固醇，已被用于治疗炎症性唇病。局部他克莫司也已用于一些炎症性唇病。
我们对特应性唇炎患者进行了回顾性临床分析。
2015 年至 2020 年间，我们共治疗了 7 例仅累及唇部的特应性皮炎患者，并诊断为特应性湿疹性唇炎。他们接受了 0.03%的他克莫司软膏治疗，完全缓解。
这些病例代表了一种报道较少的特应性/湿疹事件；文献中很少有特应性唇炎而无伴随皮肤病变的病例。我们还展示和讨论了他克莫司在局部特应性炎症性唇炎中的另一种应用。
